News | May 18, 2021
Remdesivir production increased to 119 lakh vials per month
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Dr. Reddy's has the rights to distribute 250mn doses in India
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
